author-photo

Andrew Garton

OSI Pharmaceuticals

13

Papers

559

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression

2017 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (18)
Abstract 4020: Inhibition of KIT in vivo modifies immune cell populations to improve the efficacy of checkpoint inhibitors in syngeneic mouse tumor models

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
ROCK1 and ROCK2 Are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (96)
Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.

2008 Methods in Enzymology
Show All
- Source
- Cite
- Save
Citations (12)
Inhibiteurs de kinase heterobicycliques fusionnes

2007
Show All
- Source
- Cite
- Save
Citations (0)
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

2006 Cancer Research
Show All
- Source
- Cite
- Save
Citations (334)
Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930

2005 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (42)
413 Pharmacokinetic/pharmacodynamic analysis of OSI-930, a novel selective tyrosine kinase inhibitor with anti-tumor activity

2004 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)